Avid Bioservices, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Avid Bioservices has been acquired by funds managed by GHO Capital and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion, leading to its delisting from Nasdaq.
Avid Bioservices has been acquired by funds managed by GHO Capital and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion, leading to its delisting from NASDAQ.
Avid Bioservices stockholders approved the merger agreement with GHO Capital Partners and Ampersand Capital Partners, paving the way for the company to become a wholly-owned subsidiary.
Avid Bioservices announced a 32% increase in second-quarter revenue and a definitive agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion.
Avid Bioservices has agreed to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion.
Avid Bioservices' stockholders approved amendments to the 2018 Omnibus Incentive Plan and the 2010 Employee Stock Purchase Plan, and elected directors at the 2024 Annual Meeting.
Avid Bioservices announced a 6% increase in first-quarter revenue to $40.2 million and a 16% increase in backlog to $219 million, driven by new customer acquisitions and strong process development revenue.
Avid Bioservices has amended its Deferred Compensation Plan to require that all distributions from the Company Stock Fund and deferrals of Equity Awards be made in the form of company stock.
Avid Bioservices reports record fourth-quarter revenue of $43 million and provides a positive revenue outlook for fiscal year 2025.
Avid Bioservices reported a decrease in revenue for the third quarter of fiscal year 2024, but achieved a record backlog of $206 million and completed a significant facility expansion.
Avid Bioservices received a notice from Nasdaq for failing to file its quarterly report on time, putting its listing status at risk.
Avid Bioservices has completed a private offering of $160 million in convertible senior notes due 2029, with a 7% interest rate.
Avid Bioservices will restate several past financial reports after a debt holder triggered an event of default, revealing errors in the classification of debt and accrued interest.
Avid Bioservices plans to raise $160 million through a private placement of convertible notes to repurchase and refinance its existing 2026 debt.
Avid Bioservices received a notice to immediately repay $146 million in debt due to a default, triggering a cross-default on its credit agreement and raising concerns about its financial statements.